TGFB1 and myeloid sarcoma: In concordance with previous reported studies by our own group (26), and with the objective to finally develop an autologous tolerogenic cell-therapy for MS, our results demonstrated that the generation of vitD3-tolDC in both healthy donors and MS patients did not significantly differ regarding their phenotypic and functional characteristics —with the exception of an increase on TGF-β production in healthy donor samples only—.